Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis

Chimeric antigen receptor (CAR) modified T cells targeted CD19 showed promising clinical outcomes in treatment of B cell malignances such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) and other indolent lymphomas. However, the clinical benefit varies tremendously among di...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tengfei, Cao, Ling, Xie, Jing, Shi, Ni, Zhang, Zhen, Luo, Zhenzhen, Yue, Dongli, Zhang, Zimeng, Wang, Liping, Han, Weidong, Xu, Zhongwei, Chen, Hu, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741817/
https://www.ncbi.nlm.nih.gov/pubmed/26376680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741817/
https://www.ncbi.nlm.nih.gov/pubmed/26376680

Ejemplares similares